Cases & Deals

  • Home
  • Practices
  • Celgene enforces its Revlimid® patents against Zydus Pharmaceuticals under Hatch-Waxman Act

Share

Celgene enforces its Revlimid® patents against Zydus Pharmaceuticals under Hatch-Waxman Act

March 2018

Client(s) Celgene Corporation

Jones Day is representing Celgene Corporation in a patent litigation against Zydus Pharmaceuticals and Cadila Healthcare over Revlimid®, Celgene's blockbuster drug for treating multiple myeloma and other cancers.

Celgene Corp. v. Zydus Pharmaceuticals (USA) Inc., et al., No. 2-17-cv-02528 (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.